secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-11-26T23:59:59+00:00
Accession:  0001193125-24-265612
Event type: leadership
Sentiment:  positive
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista appoints Laurence Reid, Ph.D. to Board of Directors
------------------------------------------------------------

- Laurence Reid appointed to KalVista Board effective Nov 23, 2024; term expires at 2027 annual meeting.
- Compensation: initial option for 17,000 shares, $42,500 annual cash retainer, annual option for 10,000 shares.
- Reid brings over 30 years biotech experience; was CEO of Decibel Therapeutics prior to Regeneron acquisition.
- Reid's appointment comes as KalVista progresses sebetralstat toward FDA PDUFA date of June 17, 2025.
- Board determined Reid independent under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524265612/0001193125-24-265612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524265612/d851354d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-265612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer